Reference:
Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
through 6 months. The New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345
Summary:
The BNT162b2 mRNA vaccine demonstrates high efficacy and safety against Covid-19, with a 91.3% efficacy observed over six months post-vaccination. The trial involved 44,165 participants aged 16 and older, showing consistent efficacy across diverse demographics. Safety data confirmed a favourable profile, with few serious adverse events. The vaccine’s efficacy against severe disease was 96.7%. Despite a gradual decline in efficacy over time, the findings support the continued use of BNT162b2, even amid emerging SARS-CoV-2 variants. Ongoing monitoring and studies are needed to further assess long-term efficacy and the potential need for booster doses.